Amniotics AB (publ) (AMNI.ST)
SEK 0.01
(5.88%)
SEK 0.01
(5.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.08 Million SEK | -9.79% |
| 2022 | 28.91 Million SEK | -50.22% |
| 2021 | 58.08 Million SEK | 8.68% |
| 2020 | 53.45 Million SEK | 221.63% |
| 2019 | 16.61 Million SEK | 323.79% |
| 2018 | 3.92 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q4 | 26.08 Million SEK | 9.19% |
| 2023 Q3 | 23.89 Million SEK | -9.8% |
| 2023 Q1 | 59.5 Million SEK | 105.76% |
| 2023 Q2 | 26.48 Million SEK | -55.48% |
| 2023 FY | 26.08 Million SEK | -9.79% |
| 2022 Q1 | 46.79 Million SEK | -19.44% |
| 2022 Q4 | 28.91 Million SEK | -21.43% |
| 2022 FY | 28.91 Million SEK | -50.22% |
| 2022 Q3 | 36.8 Million SEK | -14.66% |
| 2022 Q2 | 43.12 Million SEK | -7.84% |
| 2021 Q4 | 58.08 Million SEK | -14.48% |
| 2021 FY | 58.08 Million SEK | 8.68% |
| 2021 Q3 | 67.92 Million SEK | 196.82% |
| 2021 Q1 | 36.85 Million SEK | -31.05% |
| 2021 Q2 | 22.88 Million SEK | -37.91% |
| 2020 Q4 | 53.45 Million SEK | 0.0% |
| 2020 FY | 53.45 Million SEK | 221.63% |
| 2020 Q1 | - SEK | 0.0% |
| 2019 FY | 16.61 Million SEK | 323.79% |
| 2018 FY | 3.92 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 6.07 Million SEK | -329.258% |
| BioArctic AB (publ) | 1.18 Billion SEK | 97.801% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -30.163% |
| CombiGene AB (publ) | 120.61 Million SEK | 78.372% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 87.981% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 13.545% |
| OncoZenge AB (publ) | 20.34 Million SEK | -28.25% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 77.977% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 98.627% |
| Mendus AB (publ) | 755.95 Million SEK | 96.549% |
| LIDDS AB (publ) | 17.65 Million SEK | -47.754% |
| Lipum AB (publ) | 12.11 Million SEK | -115.409% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 90.642% |
| Simris Alg AB (publ) | 174.55 Million SEK | 85.055% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 50.767% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -20.196% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 96.008% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 96.591% |
| Ziccum AB (publ) | 14.97 Million SEK | -74.232% |
| AcouSort AB (publ) | 34.51 Million SEK | 24.417% |
| Active Biotech AB (publ) | 44 Million SEK | 40.714% |
| Alzinova AB (publ) | 123.18 Million SEK | 78.824% |
| Camurus AB (publ) | 1.9 Billion SEK | 98.633% |
| Cantargia AB (publ) | 223.71 Million SEK | 88.339% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -75.439% |
| Genovis AB (publ.) | 288.85 Million SEK | 90.969% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 69.392% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 81.446% |
| Intervacc AB (publ) | 259.61 Million SEK | 89.952% |
| Kancera AB (publ) | 65.64 Million SEK | 60.261% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 97.927% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 22.368% |
| NextCell Pharma AB | 81.28 Million SEK | 67.909% |
| Saniona AB (publ) | 64.14 Million SEK | 59.331% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 94.743% |
| Xintela AB (publ) | 18.39 Million SEK | -41.81% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 58.18% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 37.83% |
| Corline Biomedical AB | 100.1 Million SEK | 73.941% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 85.272% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 58.029% |
| Aptahem AB (publ) | 63.02 Million SEK | 58.61% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 92.575% |
| Fluicell AB (publ) | 9.34 Million SEK | -179.293% |
| Biovica International AB (publ) | 131.4 Million SEK | 80.149% |
| Abliva AB (publ) | 87.49 Million SEK | 70.187% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 96.569% |
| 2cureX AB (publ) | 16.62 Million SEK | -56.908% |
| I-Tech AB | 152.44 Million SEK | 82.888% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 97.438% |
| Cyxone AB (publ) | 43.65 Million SEK | 40.245% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 66.851% |
| Biosergen AB | 7.2 Million SEK | -262.255% |
| Nanologica AB (publ) | 77.42 Million SEK | 66.31% |
| SynAct Pharma AB | 228.01 Million SEK | 88.56% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 2.53% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 98.137% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 89.057% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -208.527% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 70.041% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 8.496% |